QURE - NASDAQ
uniQure N.V.
$30.41
+1.8%uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
At a Glance
Live SnapshotuniQure N.V. Management Team
Tamara Tugal
Business Development Director
Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Richard Porter
Chief Business & Scientific Officer
Compensation
$732,169
Kylie O'Keefe
Chief Customer & Strategy Officer
Matthew Craig Kapusta
Chief Executive Officer & Executive Director
Compensation
$1,052,374
Christian Klemt
Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site
Compensation
$759,950
Jeannette Potts
Chief Legal & Compliance Officer and Corporate Secretary
Compensation
$712,827
Walid Abi-Saab
Chief Medical Officer
Compensation
$945,278
Erin Boyer
Chief People & Culture Officer
Amin Abujoub
Chief Technical Operations Officer
Chiara Elizabeth Russo
Senior Director of Investor Relations
uniQure N.V. Insider Positioning
During the last 12 months, insiders have sold $628K worth of QURE shares, with no buying activity reported.
3 Months
0
0.00
25.0K
627.50K
-628K
-$628K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Abi-Saab Walid
Officer: Chief Medical Officer
$628K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $628K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
SEC Filings
QURE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | June 18, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | October 06, 2023 | November 15, 2023 | 2023 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | September 17, 2021 | October 21, 2021 | 2021 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | November 02, 2020 | December 01, 2020 | 2020 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 17, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.